People: Isis Pharmaceuticals Inc (ISIS.OQ)
ISIS.OQ on NASDAQ Stock Exchange Global Select Market
28.87USD
11:19am EDT
28.87USD
11:19am EDT
Price Change (% chg)
$-0.42 (-1.43%)
$-0.42 (-1.43%)
Prev Close
$29.29
$29.29
Open
$29.08
$29.08
Day's High
$29.18
$29.18
Day's Low
$28.73
$28.73
Volume
69,615
69,615
Avg. Vol
507,698
507,698
52-wk High
$34.30
$34.30
52-wk Low
$7.55
$7.55
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Stanley Crooke |
67 | 1991 | Chairman of the Board, President, Chief Executive Officer |
Elizabeth Hougen |
40 | 2013 | Chief Financial Officer, Senior Vice President - Finance |
B. Lynne Parshall |
58 | 2013 | Chief Operating Officer, Corporate Secretary, Director |
Patrick O'Neil |
39 | 2013 | Senior Vice President - Legal, General Counsel |
C. Frank Bennett |
56 | 2006 | Senior Vice President - Antisense Research |
Richard Geary |
55 | 2008 | Senior Vice President - Development |
Brett Monia |
51 | 2012 | Senior Vice President - Drug Discovery and Corporate Development |
Breaux Castleman |
2013 | Director | |
Spencer Berthelsen |
60 | 2002 | Independent Director |
Joseph Klein |
51 | 2005 | Independent Director |
Frederick Muto |
2001 | Independent Director | |
Joseph Wender |
67 | 1994 | Independent Director |
Wade Walke |
Executive Director - Corporate Communications |
Biographies
| Name | Description |
|---|---|
Stanley Crooke |
Dr. Stanley T. Crooke, M.D., Ph.D., is Chairman of the Board, President, Chief Executive Officer of Isis Pharmaceuticals Inc. Dr. Crooke is a founder of Isis and has been Chief Executive Officer and a Director since January 1989. He was elected Chairman of the Board in February 1991. Prior to founding Isis, from 1980 until January 1989, Dr. Crooke was employed by SmithKline Beckman Corporation, a pharmaceutical company, where his titles included President of Research and Development of SmithKline and French Laboratories. |
Elizabeth Hougen |
Ms. Elizabeth L. Hougen is Chief Financial Officer, Senior Vice President - Finance of Isis Pharmaceuticals, Inc. From January 2007 to December 2012, Ms. Hougen served as the company Vice President, Finance and Chief Accounting Officer and from May 2000 to January 2007, she served as the company Vice President, Finance. Prior to joining Isis in 2000, Ms. Hougen was Executive Director, Finance and Chief Financial Officer for Molecular Biosystems, Inc., a public biotechnology company. |
B. Lynne Parshall |
Ms. B. Lynne Parshall, J.D., is Chief Operating Officer, Corporate Secretary, Director of Isis Pharmaceuticals Inc. Ms. Parshall has served as a Director of Isis since September 2000. She has been the company Chief Operating Officer since December 2007 and previously served as the company Chief Financial Officer from June 1994 to December 2012. She also serves as the company Corporate Secretary and has served in various executive roles since November 1991. Prior to joining Isis, Ms. Parshall practiced law at Cooley LLP, outside counsel to Isis, where she was a partner from 1986 to 1991. Ms. Parshall is a member of the American, California and San Diego bar associations. |
Patrick O'Neil |
Mr. Patrick R. O'Neil, Esq., is Senior Vice President - Legal, General Counsel of Isis Pharmaceuticals Inc., since January 2013. From September 2010 to January 2013, Mr. O’Neil served as the company Vice President, Legal and General Counsel and from January 2009 to September 2010, he served as the company Vice President, Legal and Senior Transactions Counsel. From October 2001 to January 2009 he held various positions within the company Legal department. Prior to joining Isis, Mr. O’Neil was an associate at Cooley LLP. |
C. Frank Bennett |
Dr. C. Frank Bennett, Ph.D., is Senior Vice President - Antisense Research of Isis Pharmaceuticals Inc., since January 2006. From June 1995 to January 2006, Dr. Bennett served as the company Vice President, Research. From March 1993 to June 1995, he was Director, Molecular Pharmacology, and from May 1992 to March 1993, he was an Associate Director in the company Molecular and Cellular Biology department. Prior to joining Isis in 1989, Dr. Bennett was employed by SmithKline and French Laboratories in various research positions. He is an external member of the Scientific Advisory Board of Experimental Therapeutics Center in Singapore. |
Richard Geary |
Dr. Richard S. Geary, Ph.D., is Senior Vice President - Development of Isis Pharmaceuticals Inc., since August 16, 2008. From August 2003 to August 2008, Dr. Geary served as the company Vice President, Preclinical Development. From November 1995 to August 2003, he held various positions within the Preclinical Development department. Prior to joining Isis in 1995, Dr. Geary was Senior Research Scientist and Group Leader for the bioanalytical and preclinical pharmacokinetics group in the Applied Chemistry Department at Southwest Research Institute. |
Brett Monia |
Dr. Brett P. Monia, Ph.D. is the Senior Vice President, Drug Discovery and Corporate Development of Isis Pharmaceuticals Inc., since January 2012. From February 2009 to January 2012, Dr. Monia served as the company Vice President, Drug Discovery and Corporate Development and from October 2000 to February 2009, he served as the company Vice President, Preclinical Drug Discovery. From October 1989 to October 2000 he held various positions within the company Molecular Pharmacology department. |
Breaux Castleman |
Mr. Breaux B. Castleman is Director of Isis Pharmaceuticals, Inc. Mr. Castleman is president and chief executive officer of Syntiro Healthcare Services, Inc., a health care investment company, which recently sold its operations as a service provider of integrated care management and disease management. Mr. Castleman is also a director of USMD Holdings, Inc. and a senior advisor to McNally Capital LLC in Chicago. Mr. Castleman also serves as a director of FemPartners, Inc., and a senior advisor to Match Point Partners LLC in New York. Previously, he held positions as chairman of Mela Sciences, Inc., director of Med Direct, Inc., president of the Scripps Clinic, president of Caremark International's Physician Resource Group, and chief executive officer of the Kelsey-Seybold Clinic. Prior to that Mr. Castleman was the head of the Houston office of Booz Allen & Hamilton (now Booz & Co.). Mr. Castleman received a BA in economics from Yale University and attended New York University Graduate School of Business Administration. He has published articles on management issues in business and technical periodicals, including the Harvard Business Review, and has presented numerous papers and presentations to industry groups in energy, banking, healthcare, and agribusiness. |
Spencer Berthelsen |
Dr. Spencer R. Berthelsen, M.D., is an Independent Director of Isis Pharmaceuticals Inc., since May 2002. Since 1980, he has practiced Internal Medicine with the Kelsey Seybold Clinic, a 370 physician medical group based in the Texas Medical Center in Houston. Dr. Berthelsen has served in various senior leadership positions at Kelsey Seybold, including Chairman of the Department of Internal Medicine, Medical Director and Managing Director. He has been Chairman of their Board of Directors since October 2001. He has served as a Clinical Professor of Medicine at Baylor College of Medicine and the University of Texas Health Science Center of Houston. Dr. Berthelsen has served on the Board of the Texas Academy of Internal Medicine in the past and the Caremark National Pharmacy and Therapeutics Committee from 1999 through 2005. |
Joseph Klein |
Mr. Joseph Klein, III, is an Independent Director of Isis Pharmaceuticals Inc., since December 2005. Mr. Klein is currently Managing Director of Gauss Capital Advisors, LLC, a financial consulting and investment advisory firm focused on biopharmaceuticals, which he founded in March 1998. From September 2003 to December 2008, Mr. Klein also served as a Venture Partner of Red Abbey Venture Partners, L.P., a life science private equity fund. From September 2001 to September 2002, Mr. Klein was a Venture Partner of MPM Capital, a healthcare venture capital firm. From June 1999 to September 2000 when it merged with WebMD Corporation, Mr. Klein served as Vice President, Strategy, for Medical Manager Corporation, a developer of physician office management information systems. For over nine years from 1989 to 1998, Mr. Klein was a health care investment analyst at T. Rowe Price Associates, Inc., where he was the founding portfolio manager of the T. Rowe Price Health Sciences Fund, Inc. Mr. Klein serves on the board of directors of The Prospector Funds, Inc., an SEC Registered Investment Company that manages two no-load mutual funds. Mr. Klein also serves on the boards of private and non-profit entities. Within the last five years, Mr. Klein formerly served on the board of directors of five publicly held biotechnology companies: BioMarin Pharmaceutical Inc., NPS Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc., PDL BioPharma, Inc. and Savient Pharmaceuticals, Inc. |
Frederick Muto |
Mr. Frederick T. Muto is an Independent Director of Isis Pharmaceuticals Inc., since March 2001. Mr. Muto joined the law firm of Cooley LLP, outside counsel to Isis, in 1980 and became a partner in 1986. He is Chair of the firm’s Business Department, a founding partner of Cooley LLP’s San Diego office and serves on Cooley’s management committee. |
Joseph Wender |
Mr. Joseph H. Wender is an Independent Director of Isis Pharmaceuticals Inc., since January 1994. Mr. Wender began with Goldman, Sachs & Co. in 1971 and became a General Partner of that firm in 1982, where he headed the Financial Institutions Group for over a decade. Since January 2008, he has been a Senior Consultant to Goldman Sachs & Co. He is also an Independent Trustee of the Schwab Family of Funds and Director of Grandpoint Capital, a bank holding company. |
Wade Walke |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Stanley Crooke |
1,897,330 |
Elizabeth Hougen |
-- |
B. Lynne Parshall |
1,434,820 |
Patrick O'Neil |
-- |
C. Frank Bennett |
751,929 |
Richard Geary |
805,933 |
Brett Monia |
-- |
Breaux Castleman |
-- |
Spencer Berthelsen |
-- |
Joseph Klein |
-- |
Frederick Muto |
-- |
Joseph Wender |
-- |
Wade Walke |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Stanley Crooke |
753,773 | 85,162 |
Elizabeth Hougen |
0 | 0 |
B. Lynne Parshall |
448,392 | 36,716 |
Patrick O'Neil |
0 | 0 |
C. Frank Bennett |
216,954 | 57,025 |
Richard Geary |
5,044 | 5,269 |
Brett Monia |
0 | 0 |
Breaux Castleman |
0 | 0 |
Spencer Berthelsen |
0 | 0 |
Joseph Klein |
0 | 0 |
Frederick Muto |
0 | 0 |
Joseph Wender |
0 | 0 |
Wade Walke |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
CROOKE STANLEY T |
11,500 | $30.00 |
CROOKE STANLEY T |
11,500 | $11.12 |
CROOKE STANLEY T |
1,885 | $31.02 |
CROOKE STANLEY T |
1,885 | $11.12 |
CROOKE STANLEY T |
10,000 | $15.38 |
CROOKE STANLEY T |
8,115 | $15.38 |
CROOKE STANLEY T |
10,000 | $30.53 |
CROOKE STANLEY T |
8,115 | $31.02 |
CROOKE STANLEY T |
2,200 | $15.38 |
CROOKE STANLEY T |
10,000 | $30.19 |
CROOKE STANLEY T |
10,000 | $15.38 |
CROOKE STANLEY T |
2,200 | $31.40 |
CROOKE STANLEY T |
10,000 | $30.87 |
CROOKE STANLEY T |
10,000 | $15.38 |
CROOKE STANLEY T |
10,000 | $30.20 |
CROOKE STANLEY T |
10,000 | $30.02 |
CROOKE STANLEY T |
10,000 | $11.12 |
CROOKE STANLEY T |
10,000 | $11.12 |
CROOKE STANLEY T |
5,000 | $9.92 |
CROOKE STANLEY T |
44 | $15.38 |
CROOKE STANLEY T |
8,256 | $31.22 |
CROOKE STANLEY T |
44 | $31.96 |
CROOKE STANLEY T |
8,256 | $15.38 |
CROOKE STANLEY T |
5,000 | $31.96 |
CROOKE STANLEY T |
6,000 | $11.12 |

